🇺🇸 FDA
Patent

US 8987308

Compounds for the treatment of Clostridium difficile-associated disease

granted A61KA61K31/4164A61K31/424

Quick answer

US patent 8987308 (Compounds for the treatment of Clostridium difficile-associated disease) held by Summit Corporation Plc expires Mon Mar 19 2035 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Summit Corporation Plc
Grant date
Tue Mar 24 2015 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Mar 19 2035 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
15
CPC classes
A61K, A61K31/4164, A61K31/424, A61K31/4365, A61K31/437